246 related articles for article (PubMed ID: 18663146)
1. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitors.
Kindler T; Cornejo MG; Scholl C; Liu J; Leeman DS; Haydu JE; Fröhling S; Lee BH; Gilliland DG
Blood; 2008 Oct; 112(8):3373-82. PubMed ID: 18663146
[TBL] [Abstract][Full Text] [Related]
2. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
3. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
4. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
[TBL] [Abstract][Full Text] [Related]
5. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
6. Gamma Secretase Inhibitor: Therapeutic Target via NOTCH Signaling in T Cell Acute Lymphoblastic Leukemia.
Kaushik B; Pal D; Saha S
Curr Drug Targets; 2021; 22(15):1789-1798. PubMed ID: 33538669
[TBL] [Abstract][Full Text] [Related]
7. The role of NOTCH1 signaling in T-ALL.
Ferrando AA
Hematology Am Soc Hematol Educ Program; 2009; ():353-61. PubMed ID: 20008221
[TBL] [Abstract][Full Text] [Related]
8. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma.
Lin YW; Nichols RA; Letterio JJ; Aplan PD
Blood; 2006 Mar; 107(6):2540-3. PubMed ID: 16282337
[TBL] [Abstract][Full Text] [Related]
9. Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.
Pancewicz J; Taylor JM; Datta A; Baydoun HH; Waldmann TA; Hermine O; Nicot C
Proc Natl Acad Sci U S A; 2010 Sep; 107(38):16619-24. PubMed ID: 20823234
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
[TBL] [Abstract][Full Text] [Related]
11. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
12. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
Dail M; Li Q; McDaniel A; Wong J; Akagi K; Huang B; Kang HC; Kogan SC; Shokat K; Wolff L; Braun BS; Shannon K
Proc Natl Acad Sci U S A; 2010 Mar; 107(11):5106-11. PubMed ID: 20194733
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
[TBL] [Abstract][Full Text] [Related]
14. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
15. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
16. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling.
Pear WS; Aster JC
Curr Opin Hematol; 2004 Nov; 11(6):426-33. PubMed ID: 15548998
[TBL] [Abstract][Full Text] [Related]
17. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia.
Chiang MY; Xu L; Shestova O; Histen G; L'heureux S; Romany C; Childs ME; Gimotty PA; Aster JC; Pear WS
J Clin Invest; 2008 Sep; 118(9):3181-94. PubMed ID: 18677410
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
19. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
[TBL] [Abstract][Full Text] [Related]
20. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.
Palomero T; Barnes KC; Real PJ; Glade Bender JL; Sulis ML; Murty VV; Colovai AI; Balbin M; Ferrando AA
Leukemia; 2006 Jul; 20(7):1279-87. PubMed ID: 16688224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
